Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Acute Lymphoblastic Leukemia

Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells…

Date: 22nd February 2024

iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…

Date: 18th May 2023

The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation

Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies,…

Date: 10th March 2023

iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…

Date: 22nd November 2022

iwAL 2022 Session II: novel treatment strategies in ALL

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…

Date: 4th November 2022

The future of CAR-T therapy in ALL

Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been…

Date: 20th July 2022

ASH 2021: a deep dive into ALL immunotherapy

Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation…

Date: 25th March 2022

COSTEM: the role of alloHSCT in ALL

Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of…

Date: 25th October 2021

EHA 2021: targeted therapies for ALL

Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted…

Date: 1st September 2021

Key updates on CAR-T therapy for ALL

There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (around 75% of cases)….

Date: 5th July 2021

Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions

Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults…

Date: 28th May 2021

The Transplant Sessions: ASH 2020 highlights

The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…

Date: 23rd April 2021